Related Experiment Videos
Immunosuppressive effects of defibrotide
M Ferraresso1, P Rigotti, S M Stepkowski
1Department of Surgery, University of Texas Medical School, Houston 77030.
Transplantation
|October 1, 1993
Summary
Defibrotide (DF) shows immunosuppressive effects in vitro, especially with cyclosporine (CsA). Local DF combined with systemic CsA significantly improved heart transplant survival in rats.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Science
Background:
- Defibrotide (DF) is investigated for its immunomodulatory properties.
- Cyclosporine (CsA) is a standard immunosuppressant in transplantation.
- Understanding drug interactions is crucial for optimizing transplant outcomes.
Purpose of the Study:
- To evaluate the in vitro and in vivo immunosuppressive effects of defibrotide (DF) alone and in combination with cyclosporine (CsA).
- To determine the efficacy of DF and CsA in prolonging heart allograft survival in a rat model.
Main Methods:
- In vitro proliferation assays using human peripheral blood lymphocytes (PBLs) stimulated with PHA, OKT3, or alloantigens.
- In vivo heterotopic heart allograft transplantation in rats.
- Administration of DF systemically, locally via infusion pump, and in combination with CsA.
Main Results:
- DF alone inhibited PBL proliferation in vitro, particularly after OKT3 stimulation.
- The combination of DF and CsA demonstrated synergistic immunosuppressive effects in vitro (Combination Index < 0.3).
- Systemic DF administration did not prolong heart allograft survival; however, local DF combined with subtherapeutic CsA significantly increased graft survival (22.8 days vs. control).
Conclusions:
- Defibrotide exhibits immunosuppressive activity in vitro, potentiated by CsA.
- Local delivery of DF, in conjunction with systemic CsA, enhances immunosuppression and prolongs allograft survival in vivo.
- High local concentrations of DF may synergize with CsA to improve transplant outcomes.